Vibegron

Name: Vibegron | 1190389-15-1
Brand: US-CATO
SKU: S57C1106593_1_MG
Price: 19998.0 USD
Availability: InStock

Cat. No S57C1106593_1_MG

Vendor: US-CATO

Product Information

Product Name

Vibegron

Brand Name

US-CATO

Product Number

C1106593

CAS

1190389-15-1

Certificate of Analysis (COA)

COA not found

General Information

PubChem CID

44472635

IUPAC Name

(6S)-N-4-(2S,5R)-5-(R)-hydroxy(phenyl)methylpyrrolidin-2-ylmethylphenyl-4-oxo-7,8-dihydro-6H-pyrrolo1,2-apyrimidine-6-carboxamide

InChI Key

DJXRIQMCROIRCZ-XOEOCAAJSA-N

SMILES

C1CC@@H(NC@@H1CC2=CC=C(C=C2)NC(=O)C@@H3CCC4=NC=CC(=O)N34)C@@H(C5=CC=CC=C5)O

References Data Source From Pubchem

Title Not Available

Publication Name: MMW Fortschritte der Medizin

Publication Date: 2026-05

DOI: 10.1007/s15006-024-4570-3|10.1007/s15006-025-4588-1|10.1007/s15006-025-4608-1|10.1007/s15006-025-4622-3|10.1007/s15006-025-4624-1|10.1007/s15006-025-4649-5|10.1007/s15006-025-4710-4|10.1007/s15006-025-4742-9|10.1007/s15006-025-4743-8|10.1007/s15006-025-4831-9|10.1007/s15006-025-4880-0|10.1007/s15006-025-4911-x|10.1007/s15006-025-4938-z|10.1007/s15006-025-5102-5|10.1007/s15006-025-5185-z|10.1007/s15006-025-5186-y|10.1007/s15006-025-5211-1|10.1007/s15006-025-5277-9|10.1007/s15006-025-5444-z|10.1007/s15006-025-5502-6|10.1007/s15006-025-5518-y|10.1007/s15006-026-5646-z|10.1007/s15006-026-5670-z|10.1007/s15006-026-5694-4|10.1007/s15006-026-5697-1|10.1007/s15006-026-5839-5|10.1007/s15006-026-5857-3|10.1007/s15006-026-5858-2|10.1007/s15006-026-5880-4|10.1007/s15006-026-5902-2|10.1007/s15006-026-5903-1|10.1007/s15006-026-5904-0|10.1007/s15006-026-5933-8|10.1007/s15006-026-5956-1

Determining the smallest worthwhile difference of beta-3 agonist treatment for overactive bladder: a benefit-harm trade-off study

Publication Name: World Journal of Urology

Publication Date: 2026-02-16

DOI: 10.1007/s00345-026-06274-8

Reizblase – konservative und operative Therapiemöglichkeiten

Publication Name: Urologie in der Praxis

Publication Date: 2026

DOI: 10.1007/s41973-026-00327-6

Therapeutic outcomes and predictive factors of intradetrusor onabotulinumtoxinA for neurogenic detrusor overactivity (NDO) associated with spinal cord lesion

Publication Name: International Urology and Nephrology

Publication Date: 2025-12-12

DOI: 10.1007/s11255-025-04952-x

Urologic Symptom Management in Parkinson’s Disease - Current Treatments and Emerging Directions - Systematic Review

Publication Name: Current Urology Reports

Publication Date: 2025-12-03

DOI: 10.1007/s11934-025-01297-x